Innate Pharma S.A. and Sanofi announced that Sanofi has exercise one option to license a natural killer (NK) cell engager program in solid tumors from Innate's ANKET (Antibody-based NK Cell Engager Therapeutics) platform pursuant to the terms of the research collaboration and license agreement signed in December 2022. Following a research collaboration period, Sanofi will be responsible for all development, manufacturing and commercialization. Sanofi still retains the option to one additional ANKET target as per the license agreement.

Under the terms of the December 2022 agreement, Innate will receive a 15m payment for the exercise of this option. The emerging results have seen show promise at the possibility of offering options to patients who have limited treatments available to them. About ANKET: ANKET (Antib antibody-based NK cell Engager Therapeutics) is Innate's proprietary platform for developing next-generation, multi-specific natural killer (NK) cell Engager Therapeutics to treat certain types of cancer.

This versatile, fit-for-purpose technology is creating an entirely new class of molecules to induce synthetic antibody against cancer. The Company has a research collaboration and license agreement with Sanofi to apply Innate's proprietary technology to the development of innovative multi-specific antibody formats engaging NK cells through the activating receptors NKp46 and CD16 to kill tumor cells. Under the 2016 research collaboration and license agreement, Sanofi is responsible for the development, manufacturing and commercialization of products resulting from the research collaboration, IPH6101/SAR'579 (Trifunctional anti-CD123 NKp46xCD16 NK cell engager) and IPH6401/SAR'514 (Trifunctional anti -BCMA NKp46xCD16NK cell engager).

Innate Pharma is eligible to up to 400m in development and commercial milestone payments as well as royalties on net sales. As part of the license agreement entered in December 2022, Sanofi licensed IPH62 (B7-H3) and one undisclosed ANKET programs and has the option for one additional target. Under the terms of the 2022 agreement, Innate Pharma is eligible toup to 1.35 billion total in preclinical, clinical, regulatory and commercial milestones plus royalties on potential net sales.